Predictive Oncology Stock Today
| POAI Stock | USD 1.08 0.02 1.82% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Predictive Oncology is trading at 1.08 as of the 19th of May 2025. This is a 1.82 percent decrease since the beginning of the trading day. The stock's open price was 1.1. Predictive Oncology has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 18th of February 2025 and ending today, the 19th of May 2025. Click here to learn more.
Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence primarily in the United States. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota. The company has 8.93 M outstanding shares of which 202.65 K shares are at this time shorted by private and institutional investors with about 0.83 trading days to cover. More on Predictive Oncology
Moving against Predictive Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Predictive Stock Highlights
Predictive Oncology (POAI) is traded on NASDAQ Exchange in USA. It is located in 91 43rd Street, Pittsburgh, PA, United States, 15201 and employs 23 people. Predictive Oncology is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 9.65 M. Predictive Oncology conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 8.93 M outstanding shares of which 202.65 K shares are at this time shorted by private and institutional investors with about 0.83 trading days to cover.
Predictive Oncology currently holds about 25.39 M in cash with (10.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.32.
Check Predictive Oncology Probability Of Bankruptcy
Ownership AllocationRoughly 96.67 pct. of Predictive Oncology outstanding shares are held by general public with 1.27 % owned by insiders and only 2.06 (%) by third-party entities.
Check Predictive Ownership Details
Predictive Oncology Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Predictive Oncology market risk premium is the additional return an investor will receive from holding Predictive Oncology long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.11) | |||
| Jensen Alpha | (0.56) | |||
| Total Risk Alpha | (0.33) | |||
| Treynor Ratio | (0.65) |
Predictive Stock Against Markets
Predictive Oncology Corporate Management
| Joshua MBA | Interim Officer | Profile | |
| BS BSc | VP RD | Profile | |
| Pamela MBA | Chief Officer | Profile | |
| Raymond Vennare | CEO Chairman | Profile | |
| DSc OD | VP Operations | Profile | |
| Julia Kirshner | Chief Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Predictive Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in Predictive Stock please use our How to Invest in Predictive Oncology guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Predictive Oncology. If investors know Predictive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Predictive Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Predictive Oncology is measured differently than its book value, which is the value of Predictive that is recorded on the company's balance sheet. Investors also form their own opinion of Predictive Oncology's value that differs from its market value or its book value, called intrinsic value, which is Predictive Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Predictive Oncology's market value can be influenced by many factors that don't directly affect Predictive Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Predictive Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Predictive Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Predictive Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.